PD-1 bispecific antibodies combine checkpoint blockade with CTLA-4 or VEGF targeting. Can one engineered molecule offer ...
A computational and synthesis study prioritized benzohydrazide compounds 3d and 3f for experimental EGFR testing, while the lack of biological assays means their binding and anticancer activity remain ...
Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while developing new approaches for difficult-to-treat cancers such as pancreatic ...
Several Oncology Catalysts, One Earnings Question AstraZeneca PLC (NYSE:AZN) enters the3-27 European Society for Medical ...
KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established ...
Jiangsu Hengrui presents 64 research highlights at ESMO 2026, including 3 Proffered Papers, showcasing its oncology pipeline ...
A 2026 review finds that hepatitis E virus enters cells through overlapping receptor networks and counters innate immunity ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B ...
The EuroSCORE II seems to overestimate surgical risk by 26%, but the new EuroSCORE 3 may offer a better option.
HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day ...
Hengrui Pharma will present 64 research findings at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, from October ...
Dr. Norah Terrault, Chief of Gastroenterology & Hepatology, USC Keck Medical Center, said: “This is the start of a new era in treating people living with CHB. Bepirovirsen offers patients the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results